Autres langues SynAct Pharma AB

Actions

SYNACT

SE0008241491

Produits pharmaceutiques

Marché Fermé - Nasdaq Stockholm 18:00:00 01/09/2026			Varia. 5j.	Varia. 1 janv.
20,45 ^SEK	+2,25%		+7,63%	-9,51%

28/08	Synact Pharma présente de nouvelles données précliniques pour le resomelagon au WCI	FW
20/08	SynAct Pharma AB publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Autres langues

28/08	SynAct Pharma to present new resomelagon preclinical data on Phase 3-ready RA therapeutic candidate at the 17th World Congress of Inflammation 2026
20/08	SynAct Pharma (Q2 Review): Fenja Financing Backs the Post-ADVANCE Push
20/08	SynAct Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
20/08	SynAct Pharma publishes Q2 2026 interim results
19/08	SynAct Pharma: Term Sheet Signed for Brazil
19/08	SynAct Pharma progresses first commercial agreement on resomelagon for treatment of dengue in Brazil – term sheet signed
19/08	SynAct Pharma AB and Hipolabor Farmacêutica LTDA Sign Term Sheet for Co-Development and Commercialization Partnership for Treatment of Dengue In Brazil
06/08	SynAct Pharma Secures Appellate Board Backing in US Patent Application
05/08	SynAct Pharma receives favorable US patent decision for immediate-release resomelagon tablet formulation
05/08	SynAct Pharma AB Receives Favorable US Patent Decision For Immediate-Release Resomelagon Tablet Formulation
20/07	SynAct Pharma Draws SEK50 Million from New Financing Facility
20/07	SynAct comments on the SEK 100 million facility
20/07	SynAct Pharma strengthens financial position and strategic flexibility to advance partnering discussions and Phase III readiness
09/07	Resomelagon shows reduced inflammation and joint damage in osteoarthritis model
09/07	SynAct Pharma Reports Early Preclinical Results Showing Resomelagon Attenuates Osteoarthritis Associated Inflammation And Joint Damage
02/07	SynAct Pharma : Company presentation
02/07	SynAct Pharma : Bolagspresentation
30/06	Certain Shares of SynAct Pharma AB are subject to a Lock-Up Agreement Ending on 30-JUN-2026.
29/06	BIO International USA confirms growing interest in resomelagon and SynAct Pharma following the positive effects of the ADVANCE study
29/06	SynAct Pharma Provides Update Following Participation At BIO International Convention 2026 In San Diego
16/06	SynAct Pharma: Updated Base Case after ADVANCE
15/06	SynAct Pharma (Interview): ADVANCE Topline Data
15/06	SynAct Pharma: 40mg Best Dose in ADVANCE
15/06	SynAct Pharma Board of Directors and Management Enter Lock-up Agreements
15/06	SynAct Pharma : Phase 2b ADVANCE study demonstrates positive effects of resomelagon in Rheumatoid Arthritis - supports phase 3 design, regulatory interactions, and partnering